Cardiorenal Syndrome (Clinical Implications and Treatment Strategies) - Dr. G...NephroTube - Dr.Gawad
- Recorded videos of this lecture:
Arabic Language version of this lecture is available at:
https://youtu.be/8eePyMbbK_g
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
- Recorded videos of this lecture:
English Language version of this lecture is available at: https://youtu.be/YT5IlPs6F0I
Arabic Language version of this lecture is available at: https://youtu.be/HUZt4ahXlxo
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
ABO Incompatible Kidney Transplantation, Michael Casey, MD (W-0007)UF Nephrology
Welcome to the Division of Nephrology, Hypertension, & Renal Transplantation within the Department of Medicine at the University of Florida. The University of Florida is an exciting academic community filled with people passionate in their academic pursuit. The Division of Nephrology, Hypertension, & Renal Transplantation is distinguished by the impact, breadth, and depth of its clinical, training, and research programs. It is the Highest ranked Division of Nephrology within Florida, 13th top program nationally, and is comprised of distinguished faculty, all of whom are involved in patient care, research and education. Our research interests include cutting edge research and collaborations with Departments throughout the University.
For CME Credit, visit our website to register and complete the necessary requirements.
http://nephrology.medicine.ufl.edu
- English version of this lecture is available at:
https://youtu.be/V3UGzJTwAWw
- Arabic version of this lecture is available at:
https://youtu.be/hGLaUde2ue4
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Cardiorenal Syndrome (Clinical Implications and Treatment Strategies) - Dr. G...NephroTube - Dr.Gawad
- Recorded videos of this lecture:
Arabic Language version of this lecture is available at:
https://youtu.be/8eePyMbbK_g
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
- Recorded videos of this lecture:
English Language version of this lecture is available at: https://youtu.be/YT5IlPs6F0I
Arabic Language version of this lecture is available at: https://youtu.be/HUZt4ahXlxo
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
ABO Incompatible Kidney Transplantation, Michael Casey, MD (W-0007)UF Nephrology
Welcome to the Division of Nephrology, Hypertension, & Renal Transplantation within the Department of Medicine at the University of Florida. The University of Florida is an exciting academic community filled with people passionate in their academic pursuit. The Division of Nephrology, Hypertension, & Renal Transplantation is distinguished by the impact, breadth, and depth of its clinical, training, and research programs. It is the Highest ranked Division of Nephrology within Florida, 13th top program nationally, and is comprised of distinguished faculty, all of whom are involved in patient care, research and education. Our research interests include cutting edge research and collaborations with Departments throughout the University.
For CME Credit, visit our website to register and complete the necessary requirements.
http://nephrology.medicine.ufl.edu
- English version of this lecture is available at:
https://youtu.be/V3UGzJTwAWw
- Arabic version of this lecture is available at:
https://youtu.be/hGLaUde2ue4
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Infection-related Glomerulonephritis (KDIGO 2021 Guidelines) - Dr. GawadNephroTube - Dr.Gawad
- English version of this lecture is available at:
https://youtu.be/qItQlXUC2-Q
- Arabic version of this lecture is available at:
https://youtu.be/goKWRFbA4uc
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. GawadNephroTube - Dr.Gawad
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/kanEHVsStsI
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Renal Replacement Therapy: modes and evidenceMohd Saif Khan
Renal replacement therapy is a supportive care often required in critically ill patients who develop acute renal failure and its complications. Complexity arises when such patients become hemodynamically unstable and pose special challenge to critical care clinicians in ICU to carefully choose dialytic modality to tackle volume and solute overload. This presentation is about short description of modalities of RRT and current evidence regarding initiation, dose and type of modality.
- English version of this lecture is available at:
https://youtu.be/t7N2GSXhYwA
- Arabic version of this lecture is available at:
https://youtu.be/WzFZym9hDtQ
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Historical background
The concept of incremental dialysis
The residual kidney function and its significance
Incremental hemodialysis
Observational studies on incremental HD
The candidates for incremental HD
The potential benefits and risks associated with incremental HD
Incremental peritoneal dialysis
The intact nephron hypothesis in reverse
Infection-related Glomerulonephritis (KDIGO 2021 Guidelines) - Dr. GawadNephroTube - Dr.Gawad
- English version of this lecture is available at:
https://youtu.be/qItQlXUC2-Q
- Arabic version of this lecture is available at:
https://youtu.be/goKWRFbA4uc
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. GawadNephroTube - Dr.Gawad
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/kanEHVsStsI
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Renal Replacement Therapy: modes and evidenceMohd Saif Khan
Renal replacement therapy is a supportive care often required in critically ill patients who develop acute renal failure and its complications. Complexity arises when such patients become hemodynamically unstable and pose special challenge to critical care clinicians in ICU to carefully choose dialytic modality to tackle volume and solute overload. This presentation is about short description of modalities of RRT and current evidence regarding initiation, dose and type of modality.
- English version of this lecture is available at:
https://youtu.be/t7N2GSXhYwA
- Arabic version of this lecture is available at:
https://youtu.be/WzFZym9hDtQ
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Historical background
The concept of incremental dialysis
The residual kidney function and its significance
Incremental hemodialysis
Observational studies on incremental HD
The candidates for incremental HD
The potential benefits and risks associated with incremental HD
Incremental peritoneal dialysis
The intact nephron hypothesis in reverse
Renal Replacement therapy (Dialytic Management) in AKI - Dr.GawadNephroTube - Dr.Gawad
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/NN9vyWjIPbE
Arabic Language version of this lecture is available at:
https://youtu.be/i-Qlf31Vd-Y
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
In this multinational, randomized, controlled trial in patients with chronic kidney disease who were undergoing angiography, researchers found no benefit of intravenous sodium bicarbonate over intravenous sodium chloride or of oral acetylcysteine over oral placebo for the prevention of death, need for dialysis, or persistent kidney impairment at 90 days or for the prevention of contrast-associated acute kidney injury or other secondary end points.
Hepatic resections are complex surgical procedures harboring a significant risk for complications. In line with the continued development of liver surgery, hepatic resections tend to be more complex and extensive, with to this associated enhanced risk for post-hepatectomy liver failure (PHLF). Despite these improvements in outcome after major liver resection, PHLF remains one of the most serious and fatal complication of major liver resection occurring in up to 8 % of the cases.
Presentation at the Glomcon session of March 6th 2023 on microvascular inflammation after kidney transplantation and the potential adaptation of the Banff Classification
In this presentation, given for the ISN-TTS webinar on Antibody-Mediated Rejection after kidney transplantation, I discuss the phenotype of microcirculation inflammation/microvascular rejection/ABMRh in the absence of donor-specific HLA antibodies. Also the potential role of missing self activation of natural killer (NK) cells and non-HLA antibodies.
This is the presentation that I gave in Genua, which discusses the recente studies outlining the prevalence, impact, potential causes and diagnostic features of microvascular rejection after kidney transplantation, when no HLA-DSA are present.
It provides some background literature and insights for discussions on potential updates of the Banff classification of kidney transplant pathology
2018 09-20 biomarkers for post-transplant immune injuryMaarten Naesens
I discuss the paradigm of personalized (precision) medicine, and apply this to the field of kidney transplantation. I discuss risk markers, non-invasive and invasive diagnostic markers, prognostic and predictive markers.
Stockholm Karolinska meeting: Graft histology - a marker of pain and sufferin...Maarten Naesens
In this presentation, I discuss the role for protocol kidney allograft biopsies and biopsies for cause, as opportunity for individualised immunosuppressive regimen and use of targeted therapeutic strategies, in order to prevent chronic allograft dysfunction and improve long-term graft outcome. I discuss how kidney transplant histology is re-emerging as the clinical key parameter for the fate of the graft, and display long-term implications of histological alterations. I finally discuss the value of histology as a surrogate study endpoint, and reiterate the urgent need to identify appropriate surrogate endpoints to improve long-term outcomes.
Banff 2017 meeting presentation - early versus late inflammationMaarten Naesens
My presentation at the Banff 2017 meeting in Barcelona on kidney transplant pathology on the impact of time after transplantation on transplant outcome, and the difference between diagnostic and prognostic use of the Banff scheme for allograft histopathology.
HLA antistoffen en antistof-gemedieerde rejectie zijn de belangrijkste oorzaken van het falen van transplantnieren. In deze presentatie wordt een moeilijk onderwerp eenvoudig uitgelegd.
2014 06-05 Pretransplant Evaluation for Kidney Transplantation - Pretransplan...Maarten Naesens
Short overview of evidence-based decisions for the pre transplant evaluation of kidney transplant recipients. Pretransplantbilan onderzoeken niertransplantatie UZ Leuven.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
2. There are two calcineurin inhibitors currently in clinical use:
cyclosporine and tacrolimus
cyclosporine tacrolimus
3. Calcineurin inhibitors are powerful immunosuppressive agents
Calcineurin inhibitors cause renal toxicity
We should avoid calcineurin inhibitors in kidney transplants
4. The success of organ transplantation relates to the
successful development of immunosuppressive agents
5. Cyclosporine was the drug that made
kidney transplantation the first-choice treatment
6. Canadian study NEJM 1983
Azathioprine + steroids
Cyclosporine + steroids
1-year graft survival
80.4% (24% failure due to rejection)
64.0% (74% failure due to rejection*)
* 80% <50 days post-transplant
7. Calcineurin inhibitors were the first, and last drug to show
benefit in terms of kidney transplant survival
Naesens & Thaunat. Nat Rev Nephrol 2016
8. Calcineurin inhibitors were the first, and last drug to show
benefit in terms of kidney transplant survival
Naesens & Thaunat. Nat Rev Nephrol 2016
9. Calcineurin inhibitors were the first, and last drug to show
benefit in terms of kidney transplant survival
Naesens & Thaunat. Nat Rev Nephrol 2016
10. Calcineurin inhibitor nephrotoxicity was considered a main reason
for loss of kidney function after transplantation
cyclosporine
tacrolimus
Acute CNI nephrotoxicity
Chronic CNI nephrotoxicity
11. Calcineurin inhibitor nephrotoxicity was considered a main reason
for loss of kidney function after transplantation
cyclosporine
tacrolimus
Acute CNI nephrotoxicity
Chronic CNI nephrotoxicity
12. Calcineurin inhibitor nephrotoxicity was considered a main reason
for loss of kidney function after transplantation
cyclosporine
tacrolimus
Acute CNI nephrotoxicity
Chronic CNI nephrotoxicity
13. The clinical risk factors for development of
CNI nephrotoxicity have been partially elucidated
Naesens et al cJASN 2009
14. Calcineurin avoidance, minimization and conversion
was a main goal in clinical research in the years after ’00
Time after transplantation
Drug levels
Other drug
CNI Other drug
CNI avoidance
CNI minimization
CNI conversion
CNI (Tac, CsA)
Other drug (mTORi, belatacept etc.)
Day 0
Other drug
CNI
15. Calcineurin avoidance, minimization and conversion
was a main goal in clinical research in the years after ’00
Time after transplantation
Drug levels
Other drug
CNI Other drug
CNI avoidance
CNI minimization
CNI conversion
CNI (Tac, CsA)
Other drug (mTORi, belatacept etc.)
Day 0
Other drug
CNI
16. Calcineurin avoidance: the Symphony study demonstrated
superior outcome with CNIs than without
Ekberg et al NEJM 2007
17. Calcineurin avoidance: the Symphony study demonstrated
superior outcome with CNIs than without
(C0 4-8)
(C0 3-7)
(C0 50-100)
(C0 100-200)
Ekberg et al NEJM 2007 & AJT 2009
(C0 4-8)
(C0 3-7)
(C0 50-100)
(C0 100-200)
18. Calcineurin avoidance: the Symphony study demonstrated
superior outcome with CNIs than without
Sharif et al JASN 2011
19. Belatacept is a new drug on the market,
with very different profile than previous immunosuppressants
Naesens & Thaunat. Nat Rev Nephrol 2016
20. Belatacept is a new drug on the market,
with very different profile than previous immunosuppressants
Naesens & Thaunat. Nat Rev Nephrol 2016
21. Belatacept is a new drug on the market,
with very different profile than previous immunosuppressants
7 years FUNaesens & Thaunat. Nat Rev Nephrol 2016
22. The rejections in the BENEFIT study were T-cell mediated
with low risk of DSA formation
Vincenti F et al. N Eng J Med 2016
BELA MI BELA LI CsA
0%
5%
10%
15%
20%
14%
9%
6%
Acute rejection occurence
BELA MI BELA LI CsA
0%
5%
10%
15%
20%
1.4%
3.1%
11.6%
De novo DSA occurence
***
*
23. The rejections in the BENEFIT study were T-cell mediated
with low risk of DSA formation
Vincenti F et al. N Eng J Med 2016
No difference in ABMR!
BELA MI BELA LI CsA
0%
5%
10%
15%
20%
14%
9%
6%
Acute rejection occurence
BELA MI BELA LI CsA
0%
5%
10%
15%
20%
1.4%
3.1%
11.6%
De novo DSA occurence
***
*
***
24. The BENEFIT study confirms the beneficial
effect of belatacept in terms of eGFR
Vincenti et al NEJM 2016
25. Belatacept is the first IS agent to show
improved overall graft survival since CsA
Patient survival Graft survival
P = 0.06 P = NS
Vincenti et al NEJM 2016
26. Conclusion: CNI avoidance was not successful,
only belatacept shows some promise
Time after transplantation
Drug levels
Other drug
CNI Other drug
CNI avoidance
CNI minimization
CNI conversion
CNI (Tac, CsA)
Other drug (mTORi, belatacept etc.)
Day 0
Other drug
CNI
27. CNI conversion = stop CNI and replace with other IS
Time after transplantation
Drug levels
Other drug
CNI Other drug
CNI avoidance
CNI minimization
CNI conversion
CNI (Tac, CsA)
Other drug (mTORi, belatacept etc.)
Day 0
Other drug
CNI
28. Conversion from CNI to mTORi leads to better renal function
Sawinski et al Am J Transplant 2016
And similar acute rejection
And similar graft survival
29. Budde et al Lancet 2011; AJT 2014
Conversion from CNI to mTORi leads to better renal function
30. Conversion from CNI to mTORi leads to more rejection?
Sawinski et al Am J Transplant 2016
31. Grinyo et al Am J Kidney Dis 2017
Conversion from CNI to belatacept leads to better eGFR
And similar acute rejection
And similar graft survival
32. Conclusion: CNI conversion improves graft function
but does not improve graft or patient survival
Time after transplantation
Drug levels
Other drug
CNI Other drug
CNI avoidance
CNI minimization
CNI conversion
CNI (Tac, CsA)
Other drug (mTORi, belatacept etc.)
Day 0
Other drug
CNI
33. Conclusion: CNI withdrawal (not replacing by another IS)
is not safe
Time after transplantation
Drug levels
Other drug
CNI
CNI avoidance
CNI minimization
CNI withdrawal
CNI (Tac, CsA)
Other drug (mTORi, belatacept etc.)
Day 0
Other drug
CNI
Increased risk of BPAR (x3)
34. CNI minimization: add another immunosuppressant
to lower level CNI
Time after transplantation
Drug levels
Other drug
CNI Other drug
CNI avoidance
CNI minimization
CNI conversion
CNI (Tac, CsA)
Other drug (MPA, mTORi, belatacept etc.)
Day 0
Other drug
CNI
35. Low CNI + MPA = better renal function
Sawinski et al Am J Transplant 2016
36. Low CNI + MPA = lower risk of graft failure
Sawinski et al Am J Transplant 2016
37. CNI + mTORi = a nephrotoxic combination
Kahan et al Lancet 2000
40
45
50
55
60
65
70
75
2 mg SIR 5 mg SIR AZA
GFR
(mL/min) 6 months
12 months
**
*
***
***
39. Sharif et al JASN 2011
Sir+T
Eve+C
Sir+T
Eve+C
Eve+T
Meta-analyses suggests benefit of CNI minimization
for kidney transplantation
Sharif et al JASN 2011
40. TRANSFORM: low-dose CNI + low-dose EVR in
the largest trial ever in kidney transplantation
Abstract LOS001; Pascual et al.
41. TRANSFORM: low-dose CNI + low-dose EVR in the largest
trial ever in kidney transplantation: equal primary endpoint
Abstract LOS001; Pascual et al.
Composite of eGFR <50 mL/min/1.73 m2 or tBPAR†
42. TRANSFORM: low-dose CNI + low-dose EVR in the largest
trial ever in kidney transplantation: equal graft function
Abstract LOS010; Oppenheimer et al.
Mean difference in eGFR at M12:
−1.39 (−3.29, 0.51), P = 0.15
43. TRANSFORM: low-dose CNI + low-dose EVR in the largest
trial ever in kidney transplantation: lower infection risk
Abstract LOS002; Cruzado et al.
44. Calcineurin avoidance, minimization and conversion
was a main goal in clinical research in the years after ’00
Time after transplantation
Drug levels
Other drug
CNI
CNI withdrawal
CNI (Tac, CsA)
Other drug (mTORi, belatacept etc.)
Day 0
CNI avoidance
- mTORi
- belatacept ✓
45. Calcineurin avoidance, minimization and conversion
was a main goal in clinical research in the years after ’00
Time after transplantation
Drug levels
Other drug
CNI Other drug
CNI minimization
CNI conversion
- mTORi
- belatacept
CNI (Tac, CsA)
Other drug (mTORi, belatacept etc.)
Day 0
Other drug
CNI ✓
?
CNI avoidance
- mTORi
- belatacept ✓
46. mTORi use in kidney transplantation is declining
Hart et al Am J Transplant 2015
mTORi use (US – SRTR data)
47. CNI use in kidney transplantation is virtually universal
Hart et al Am J Transplant 2015
CNI use (US – SRTR data)
This title was given to me by the organizers of this congress. I did not choose it myself, and I have to say that the title seems to give me somewhat limited freedom of speech and free thinking. In this presentation, I will discuss with you what I really think about this statement.
I admire those of you that are here without being involved in this clinical problem. To sit here, in beautiful Nice, with a presentation that does not affect you. Either the rest of the program this morning is uninteresting, or it must be raining outside.
Of course, Hopital Necker uses this. I suppose they do everything that is possible, including this. But the fact that so few of you actually use biopsies for decision-making on kidney allocation, is very different than current practice in the US.
Sawinski et al AJT 2016: We evaluated 92 comparisons from 88 randomized controlled trials and found
moderate- to high-strength evidence suggesting that minimization strategies result in better clinical outcomes compared with standard-dose regimens;
moderate-strength evidence indicating that conversion to a mammalian target of rapamycin inhibitor or belatacept was associated with improved renal function but increased rejection risk; and
moderate- to high-strength evidence suggesting planned CNI withdrawal could result in improved renal function despite an association with increased rejection risk.
The evidence base for avoidance studies was insufficient to draw meaningful conclusions.
The applicability of the review is limited by the large number of studies examining cyclosporine-based strategies and low-risk populations.
Additional research is needed with tacrolimus-based regimens and higher risk populations.
The non-inferiority trial design actually saved the whole study, and the future of belatacept. Without this non-inferiority, the study would have failed and we would have had approval for this still promising but little used drug.
Superiority for GFR, as illustrated in the beginning of my presentation.
Shows that this is still a drug with great potential in the field of transplantation.
A very important lesson that we learn from the BENEFIT study is however that TCMR is not a good endpoint, certainly not in this low-risk population
Background: In a phase 2 study, kidney transplant recipients of low immunologic risk who switched from a
calcineurin inhibitor (CNI) to belatacept had improved kidney function at 12 months postconversion versus
those continuing CNI therapy, with a low rate of acute rejection and no transplant loss.
Study Design: 36-month follow-up of the intention-to-treat population.
Setting & Participants: CNI-treated adult kidney transplant recipients with stable transplant function
(estimated glomerular filtration rate [eGFR], 35-75 mL/min/1.73 m2).
Interventions: At 6 to 36 months posttransplantation, patients were randomly assigned to switch to
belatacept-based immunosuppression (n 5 84) or continue CNI-based therapy (n 5 89).
Outcomes: Safety was the primary outcome. eGFR, acute rejection, transplant loss, and death were also
assessed.
Measurements: Treatment exposure2adjusted incidence rates for safety, repeated-measures modeling for
eGFR, Kaplan-Meier analyses for efficacy.
Results: Serious adverse events occurred in 33 (39%) belatacept-treated patients and 36 (40%) patients in
the CNI group. Treatment exposure2adjusted incidence rates for serious infections (belatacept vs CNI, 10.21
vs 9.31 per 100 person-years) and malignancies (3.01 vs 3.41 per 100 person-years) were similar. More
patients in the belatacept versus CNI group had any-grade viral infections (14.60 vs 11.00 per 100 personyears).
No posttransplantation lymphoproliferative disorder was reported. Belatacept-treated patients had a
significantly greater estimated gain in mean eGFR (1.90 vs 0.07 mL/min/1.73 m2 per year; P for time-bytreatment
interaction effect 5 0.01). The probability of acute rejection was not significantly different for
belatacept (8.38% vs 3.60%; HR, 2.50 [95% CI, 0.65-9.65; P 5 0.2). HR for the comparison of belatacept
to the CNI group for time to death or transplant loss was 1.00 (95% CI, 0.14-7.07; P 5 0.9).
Limitations: Exploratory post hoc analysis with a small sample size.
Conclusions: Switching patients from a CNI to belatacept may represent a safe approach to immunosuppression
and is being further explored in an ongoing phase 3b trial.
NB. Withdrawal, not replacing by another drug (and continue with only MMF), was tried but highly significant risk of BPAR. eGFR somewhat better, and impact on survival fully unclear.
NB. Withdrawal, not replacing by another drug (and continue with only one IS), was tried but highly significant risk of BPAR:
X 3 with only MMF
X 1.7 with only mTORi
(according to Sawinski et al).
eGFR somewhat better, and impact on survival fully unclear.